Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin

We report the results of a prospective, randomized phase 3 trial evaluating the use of gemtuzumab ozogamicin (GO) in an intensive consolidation approach in 657 patients 17-60 years of age. Patients in first complete remission (CR1) after cytarabine and standard- or high-dose daunorubicin induction r...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Fernandez, Hugo F., Sun, Zhuoxin, Litzow, Mark R., Luger, Selina M., Paietta, Elisabeth M., Racevskis, Janis, Dewald, Gordon, Ketterling, Rhett P., Rowe, Jacob M., Lazarus, Hillard M., Tallman, Martin S.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2011
Teme:
Clinical Trials and Observations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3109705/
https://ncbi.nlm.nih.gov/pubmed/21415269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-09-309229
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki